Oncogene:在前列腺癌中,COX-2能够调控PKCε的促肿瘤作用

2018-05-28 AlexYang MedSci原创

促肿瘤激酶PKCε在人类前列腺癌中是过表达的,并且在前列腺癌的发展过程中与肿瘤抑制因子Pten功能丧失协作。然而,促使PKCε调控表型的效应因子到目前为止仍旧不清楚。最近,有研究人员利用细胞学和小鼠模型,展示了PKCε的过表达与Pten功能丧失协同起作用,共同促进NF-κB激活和诱导环氧合酶-2(COX-2)的表达以及表型特性,这些表型特性在人类前列腺肿瘤中同样能够观察到。在前列腺癌细胞中靶向干扰

促肿瘤激酶PKCε在人类前列腺癌中是过表达的,并且在前列腺癌的发展过程中与肿瘤抑制因子Pten功能丧失协作。然而,促使PKCε调控表型的效应因子到目前为止仍旧不清楚。

最近,有研究人员利用细胞学和小鼠模型,展示了PKCε的过表达与Pten功能丧失协同起作用,共同促进NF-κB激活和诱导环氧合酶-2(COX-2)的表达以及表型特性,这些表型特性在人类前列腺肿瘤中同样能够观察到。在前列腺癌细胞中靶向干扰PKCε能够损伤COX-2诱导作用和PGE2的表达。明显地是,COX-2抑制剂能够选择性的杀死过表达PKCε的前列腺上皮细胞,并且该能力可以通过Pten功能丧失得到巨大的增强。长期的COX-2抑制在前列腺特异性PKCε表达小鼠模型中能够显著的减少腺癌的形成、血管再生和Pten功能丧失。

最后,研究人员指出,他们的结果为标准的NF-κB通路和作为PKCε效应因子的靶标基因COX2参与致瘤过程提供了强有力的证据,并且强调了在前列腺癌的化学预防和化疗中使用COX抑制剂时,PKCε具有作为一个有用的生物标记的潜力。

原始出处:

Rachana Garg, Jorge M. Blando, Carlos J. Perez et al. COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer. Oncogene. 16 May 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049031, encodeId=0ac720490311d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 03 10:18:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533676, encodeId=c6b215336e64d, content=<a href='/topic/show?id=34e6514391' target=_blank style='color:#2F92EE;'>#COX-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5143, encryptionId=34e6514391, topicName=COX-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544412475251, createdName=手留余香, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558116, encodeId=5edb155811629, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319595, encodeId=91d931959500, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:43:21 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319462, encodeId=25673194625f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon May 28 22:50:01 CST 2018, time=2018-05-28, status=1, ipAttribution=)]
    2019-03-03 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049031, encodeId=0ac720490311d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 03 10:18:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533676, encodeId=c6b215336e64d, content=<a href='/topic/show?id=34e6514391' target=_blank style='color:#2F92EE;'>#COX-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5143, encryptionId=34e6514391, topicName=COX-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544412475251, createdName=手留余香, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558116, encodeId=5edb155811629, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319595, encodeId=91d931959500, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:43:21 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319462, encodeId=25673194625f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon May 28 22:50:01 CST 2018, time=2018-05-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049031, encodeId=0ac720490311d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 03 10:18:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533676, encodeId=c6b215336e64d, content=<a href='/topic/show?id=34e6514391' target=_blank style='color:#2F92EE;'>#COX-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5143, encryptionId=34e6514391, topicName=COX-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544412475251, createdName=手留余香, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558116, encodeId=5edb155811629, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319595, encodeId=91d931959500, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:43:21 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319462, encodeId=25673194625f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon May 28 22:50:01 CST 2018, time=2018-05-28, status=1, ipAttribution=)]
    2018-05-30 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049031, encodeId=0ac720490311d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 03 10:18:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533676, encodeId=c6b215336e64d, content=<a href='/topic/show?id=34e6514391' target=_blank style='color:#2F92EE;'>#COX-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5143, encryptionId=34e6514391, topicName=COX-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544412475251, createdName=手留余香, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558116, encodeId=5edb155811629, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319595, encodeId=91d931959500, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:43:21 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319462, encodeId=25673194625f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon May 28 22:50:01 CST 2018, time=2018-05-28, status=1, ipAttribution=)]
    2018-05-29 kafei

    学习了谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2049031, encodeId=0ac720490311d, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Mar 03 10:18:00 CST 2019, time=2019-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533676, encodeId=c6b215336e64d, content=<a href='/topic/show?id=34e6514391' target=_blank style='color:#2F92EE;'>#COX-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5143, encryptionId=34e6514391, topicName=COX-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=544412475251, createdName=手留余香, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558116, encodeId=5edb155811629, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Wed May 30 13:18:00 CST 2018, time=2018-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319595, encodeId=91d931959500, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Tue May 29 07:43:21 CST 2018, time=2018-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319462, encodeId=25673194625f, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Mon May 28 22:50:01 CST 2018, time=2018-05-28, status=1, ipAttribution=)]
    2018-05-28 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

Prostate Cancer P D:前列腺癌初级病灶治疗应该选择哪项技术?

随着前列腺癌(PCa)局部重点治疗(FT)兴趣的增加,不同治疗形式相关的设备正在增加,包括高强度聚焦超声(HIFU)、冷冻疗法、焦激光烧蚀(FLA)、不可逆电穿透技术(IRE)、血管靶向光动力治疗(VTP)、焦近距离放射疗法(FBT)和烧蚀定向放疗(SABR)。目前,针对病人个体特性选择哪种技术的建议还没有很明确的研究。最近,有研究人员在文献中回顾了不同技术的特殊作用,从而根据病人个体肿瘤特性选择

盘点:近期前列腺癌治疗及机理一览

前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展,与大家一起分享学习!【1】Prostate Cancer P D: 免疫检查点阻断结合冷冻

Nat Genet:同期2篇论文全面解读前列腺癌的致病基因和突变

全球范围内,前列腺癌发病率逐年升高。在美国,前列腺癌发病率位于男性肿瘤第一位, 死亡率位于第二。据美国癌症协会估计, 2018 年美国会有 16.55万例新发前列腺癌, 并会有 2.94万人死于前列腺癌。在中国,根据我国癌症协会2015年估计,前列腺癌发病率排名第六,死亡率位于第十。前列腺癌已成为严重威胁全球中老年男性健康的疾病。

前列腺癌经典内分泌治疗安全共识

为了进一步抑制前列腺癌患者机体下丘脑-垂体-睾丸轴以外雄激素的作用,甾体类(雌激素、孕酮等)和非甾体类抗雄药物(比卡鲁胺、氟他胺、尼鲁米特)先后被尝试在前列腺癌内分泌临床治疗中与手术/药物去势联合应用(CAB)。由于非甾体类药物在疗效和安全性方面的明显优势,非甾体类药物已经成为前列腺癌联合内分泌治疗的首选。 尽管由LHRH 激动剂、睾丸去势手术和非甾体类/甾体类抗雄药物单独或联合使用已经成为治疗前

Sci Rep:真核生物翻译起始因子4伽马1(eIF4G1)在前列腺癌恶化过程中表达上调并且调控细胞生长和转移

eIF4G1是 eIF4F复合物的一个关键的组分,并且在帽依赖的mRNA翻译过程中是需要的,上述过程在肿瘤生长和生存中是必须的过程。然而,eIF4G1在前列腺癌(PCa)中的角色仍旧没有被评估过。最近,研究人员在PCa组织中发现,与正常组织相比,eIF4G1蛋白的表达水平增加。TCGA数据分析阐释了eIF4G1基因表达与更高的肿瘤等级和阶段呈现正相关关系。更进一步的是,eIF4G1在16%的转移性

Sci Rep:开始诊断的黑色素瘤能够增加随后患前列腺癌风险

越来越多的证据表明,皮肤黑色素瘤的诊断(CM)也许与前列腺癌的发生率(PC)相关。最近,有研究人员调查了是否CM的发生率与随后PC风险的增加相关。研究人员利用来自新南威尔士癌症数据库中的所有CM和PC案例数据进行了分析,这些案例都在1972年和2008年之间诊断。研究人员针对PC发生率计算了年龄标准化发生率(SIR)和95%置信区间(95% CI)。另外,研究人员还根据指定的社会人口统计学分类和疾